Rocket Fuel
Prescribing
Information
Instructions
for Use
Important Safety
Information
Amgen
MedInfo
Prescribing Information Instructions for Use Important Safety Information Amgen MedInfo Live Assistance For Patients
Questions about Neulasta?

Access for your patients

Neulasta® patients who need financial assistance for the Neulasta® Onpro™ kit or prefilled syringe for manual injection may be eligible for support from several sources. These include:

  • Independent co-pay foundations
  • The Safety Net Foundation, which provides Neulasta® at no cost for eligible patients
  • The Neulasta FIRST STEP® Co-Pay Coupon Program

Learn more about the Neulasta® Onpro™ kit.

89% of Neulasta® patients had $0 out-of-pocket costs, based on a national claims database*1

*Estimated amount of Medicare beneficiaries with supplemental coverage and commercially insured patients with no out-of-pocket cost, based on Oncology Clinic data provided by IMS looking at 835 Remittance Advise and pre-adjudicated 837 Claim Forms in a Report dated August 1, 2014. Does not include costs related to office visit, physician, staff, or administrative charges associated with administering Neulasta.

Your patients may be eligible for the Neulasta® Co-Pay Coupon Program

The Neulasta FIRST STEP® Program is a co-pay coupon program to help commercially insured eligible patients with their deductible, co-insurance, and/or co-pay requirements for Neulasta® (pegfilgrastim).

Access coding and billing information for Neulasta.

Download the formulary fact sheet for Neulasta (includes Neulasta® Onpro™ kit and prefilled syringe for manual injection).

Enrolling your practice

To enroll your practice in the Amgen FIRST STEP® Program, please call 1-888-65-STEP1 (1-888-657-8371). Offices must complete this process once prior to processing the Amgen FIRST STEP® Program Cards.

  Next:

Learn about assistance for uninsured patients

Reference:

  1. Data on file, Amgen.
Important Safety Information
SEE MORE

Contraindication

Do not administer Neulasta® to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.